Hims & Hers Health, Inc. (HIMS)
| Market Cap | 7.88B -19.6% |
| Revenue (ttm) | 2.58B +28.0% |
| Net Income | -142.03M |
| EPS | -0.62 |
| Shares Out | 233.31M |
| PE Ratio | n/a |
| Forward PE | 81.54 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,694,925 |
| Open | 31.67 |
| Previous Close | 31.86 |
| Day's Range | 31.60 - 34.46 |
| 52-Week Range | 13.74 - 65.30 |
| Beta | 2.42 |
| Analysts | Hold |
| Price Target | 30.85 (-8.67%) |
| Earnings Date | Aug 10, 2026 |
About HIMS
Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and de... [Read more]
Financial Performance
In 2025, Hims & Hers Health's revenue was $2.35 billion, an increase of 59.00% compared to the previous year's $1.48 billion. Earnings were $128.37 million, an increase of 1.85%.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for HIMS stock is "Hold." The 12-month stock price target is $30.85, which is a decrease of -8.67% from the latest price.
News
Berger Montague PC Investigates Hims & Hers Health, Inc.'s Board of Directors for Breach of Fiduciary Duty (HIMS)
Philadelphia, Pennsylvania--(Newsfile Corp. - August 19, 2026) - National plaintiffs' law firm Berger Montague PC announces an investigation into the Board of Directors of Hims & Hers Health, Inc. (NY...
Watch CNBC's full interview with Hims & Hers CEO Andrew Dudum
In an exclusive interview, Hims & Hers CEO Andrew Dudum sits down with Squawk Box Co-Anchor Andrew Ross Sorkin and shares his perspective on how AI can transform healthcare, the company's transition f...
Hims & Hers CEO says FTC lawsuit misunderstands how the company works
Hims & Hers CEO Andrew Dudum defended the company against against an FTC lawsuit over its data sharing and subscription practices. In an interview with CNBC, he also said the company's sale of compoun...
As Hims prepares for peptides launch, Wall Street cautious on prospects this year
Hims & Hers Health plans to offer some legally available peptides in 2026, but investors and analysts who spoke to Reuters after the telehealth company's quarterly results this week said sales for th...
Berger Montague PC Investigates Hims & Hers Health, Inc.'s Board of Directors for Breach of Fiduciary Duty (NYSE: HIMS)
PHILADELPHIA, Aug. 12, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces an investigation into the Board of Directors of Hims & Hers Health, Inc. (NYSE: HIMS) ("Hims & He...
Tuesday's Morning Movers: RKLB & HIMS Earnings, RIOT Gets Anthropic Deal
Hims & Hers (HIMS) shares struggled to find their footing after the company posted a quarterly loss despite seeing revenue and guidance rise. Sam Vadas discusses the earnings and the price action foll...
Hims & Hers shares slide as costly weight-loss push squeezes margins
Hims & Hers Health's shares fell nearly 7% in premarket trading on Tuesday, as concerns over shrinking profit margins overshadowed strong subscriber growth and a raised annual revenue forecast.
AST SpaceMobile, Intel, On, Hims, and More Stocks That Explain Today's Market
Stocks looked set to struggle for direction on Tuesday as investors worried about inflation, with hopes of Iran agreeing a deal to reopen the crucial Strait of Hormuz shipping route fading fast.
Hims & Hers stock drops 7% despite higher guidance: what went wrong?
Shares of Hims & Hers Health fell more than 7% in premarket trading on Tuesday after the telehealth company reported a wider-than-expected second-quarter loss, as investments in branded GLP-1 weight-l...
Hims & Hers Health Earnings Call Transcript: Q2 2026
Q2 2026 saw 40% revenue growth to $753M and nearly 3M subscribers, driven by AI-powered care, international expansion, and strong weight loss and hormonal health demand. Adjusted EBITDA margin improved to 8%, with guidance raised for 2026 and robust investments in technology and global scale.
Hims & Hers Health Slides: Q2 2026
Hims & Hers Health has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 10, 2026.
Hims & Hers Health Earnings release: Q2 2026
Hims & Hers Health released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Hims & Hers Health Quarterly report: Q2 2026
Hims & Hers Health has published its Q2 2026 quarterly earnings report on August 10, 2026.
Hims & Hers Health Boosts Revenue Target, Swings to Second-Quarter Loss
The telehealth platform said it now projects $3.1 billion to $3.3 billion in revenue for the year, up from a previous target for $2.8 billion to $3 billion.
Hims & Hers raises annual forecast revenue on strong subscriber growth
Hims & Hers Health on Monday posted second-quarter revenue above estimates and raised its annual revenue forecast, as the telehealth company benefited from an increase in subscribers and expanding i...
Hims & Hers Health, Inc. Reports Second Quarter 2026 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS), the leading global health and wellness platform, today announced financial results for the second...
Raul Shah on HIMS Earnings Expectations & GLP-1 Wave's Lasting Stock Impacts
Raul Shah discusses expectations for Hims & Hers (HIMS) into earnings after Monday's closing bell. He believes the telehealth company is well-positioned thanks to the GLP-1 wave, arguing investors are...
Kaplan Fox Notifies Hims & Hers Health, Inc. (HIMS) Investors of a Securities Investigation into the Company
New York, New York--(Newsfile Corp. - August 7, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (...
Lowey Dannenberg, P.C. is Investigating Hims & Hers Health, Inc. (NYSE: HIMS) for Potential Violations of the Federal Securities Laws
NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating Hims & Hers Health, Inc. (NYSE: HIMS) (“Hims...
Hims & Hers Introduces New Hers App with First-of-Its-Kind, Doctor-Led, AI-Native Care Experience
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers, the leading health and wellness platform, today announced a first-of-its-kind* intelligent care experience that puts AI directly inside customers' care, no...
Kaplan Fox Announces a Securities Investigation into Hims & Hers Health, Inc. (HIMS) - Investors Encouraged to Contact the Firm
New York, New York--(Newsfile Corp. - August 3, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (...
Market Matters Ep. 12: How HIMS Could Benefit From FDA Changes
Raul Shah (@Raul_DSF) CEO of DocShah Financial, analyzes the potential Wall Street implications of the FDA's impending decision on peptide regulation, takes a closer look at how Hims & Hers could ben...
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $HIMS--HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with SBS Law.
FTC sues Hims & Hers for allegedly sharing patients' medical data with advertisers Meta and Snap
The Federal Trade Commission is suing healthcare giant Hims & Hers for allegedly sharing its customers' medical and healthcare information with advertisers and tech giants, like Meta and Snap, as well...
Hims & Hers sent users' health data to social media giants despite promising privacy, bombshell FTC lawsuit claims
Hims & Hers stock added to losses after the news and was trading down around 12%.